Paid Advertisement on behalf of:

LIR Life Sciences

Advancing obesity treatment with an exclusive novel platform delivery system, a holistic and innovative approach to drug delivery.

Become an Investor

Paid Advertisement on behalf of:

LIR Life Sciences

Advancing obesity treatment with an exclusive novel platform delivery system, a holistic and innovative approach to drug delivery.

Become an Investor

LIR Life Sciences Corp

CSE:

SKNY

FSE:

N790

CSE:

SKNY

FSE:

N790

Building long-term value through next-generation drug delivery

LIR Life Sciences Corp. is a Vancouver-based biotechnology company focused on developing, researching, and advancing novel, needle-free drug delivery platforms for obesity treatment across global markets.

The company is building a portfolio of transdermal and alternative delivery technologies designed to deliver proven GLP-1 and GIP-based therapies in more accessible, affordable, and patient-friendly formats. LIR’s strategy prioritizes platform scalability, compatibility with multiple existing and future incretin-based medicines, and partnerships with leading academic institutions.

By leveraging FDA-approved compounds with innovative delivery mechanisms, LIR Life Sciences aims to reduce development risk while addressing one of the largest and fastest-growing unmet needs in global healthcare.

0.0B

Projected GLP-1 Market by 2030

0.0B

Affected by Obesity by 2035

Subscribe for Updates

The Obesity Treatment Shift

Obesity rates continue to rise globally, driving increased demand for effective, long-term treatment solutions. While GLP-1 therapies have transformed obesity care, their reliance on injections, cold-chain logistics, and high annual costs creates meaningful barriers to access and adherence for millions of patients.

LIR Life Sciences operates at the forefront of obesity and metabolic care, developing scalable solutions to expand patient access and improve long-term outcomes.

Become an Investor

Our Innovative Approach

Innovating the Future of Obesity Treatment

LIR Life Sciences is developing non-injectable GLP-1 therapies using proprietary transdermal and sublingual delivery platforms, designed to improve access, reduce treatment complexity, and enhance patient experience within a rapidly growing global obesity market.

SystemLS™

In airfreight, the only constant is change – it's the heartbeat of the sector.

SystemLS™

In airfreight, the only constant is change – it's the heartbeat of the sector.

SystemLS™

In airfreight, the only constant is change – it's the heartbeat of the sector.

SystemLS™

In airfreight, the only constant is change – it's the heartbeat of the sector.

SystemLS™

In airfreight, the only constant is change – it's the heartbeat of the sector.

SystemLS™

In airfreight, the only constant is change – it's the heartbeat of the sector.

SystemLS™

In airfreight, the only constant is change – it's the heartbeat of the sector.

SystemLS™

In airfreight, the only constant is change – it's the heartbeat of the sector.

SystemLS™

In airfreight, the only constant is change – it's the heartbeat of the sector.

Azurene

Azurene Immunity Booster Traveller

Azurene

Azurene Immunity Booster Traveller

Azurene

Azurene Immunity Booster Traveller

Investor Highlights

CSE:

SKNY

FSE:

N790

Large, High-Growth Market Exposure

Targeting the global GLP-1 obesity market projected to reach $156.7B by 2030, driven by rising obesity prevalence and long-term chronic care demand.

De-Risked Development Strategy

Focuses on FDA-approved GLP-1 compounds with novel delivery mechanisms, potentially reducing regulatory risk, development timelines, and capital intensity versus new molecular entities.

Differentiated, Needle-Free Platform

Proprietary cell-penetrating peptide (CPP) technology enables transdermal and alternative delivery of proven GLP-1/GIP therapies—addressing major adherence, access, and convenience barriers.

World-Class Scientific & Global Health Leadership

Leadership and advisors with 700+ peer-reviewed publications, deep clinical trial expertise, and global health commercialization experience across both developed and emerging markets.

Large, High-Growth Market Exposure

Targeting the global GLP-1 obesity market projected to reach $156.7B by 2030, driven by rising obesity prevalence and long-term chronic care demand.

De-Risked Development Strategy

Focuses on FDA-approved GLP-1 compounds with novel delivery mechanisms, potentially reducing regulatory risk, development timelines, and capital intensity versus new molecular entities.

Differentiated, Needle-Free Platform

Proprietary cell-penetrating peptide (CPP) technology enables transdermal and alternative delivery of proven GLP-1/GIP therapies—addressing major adherence, access, and convenience barriers.

World-Class Scientific & Global Health Leadership

Leadership and advisors with 700+ peer-reviewed publications, deep clinical trial expertise, and global health commercialization experience across both developed and emerging markets.

Large, High-Growth Market Exposure

Targeting the global GLP-1 obesity market projected to reach $156.7B by 2030, driven by rising obesity prevalence and long-term chronic care demand.

Differentiated, Needle-Free Platform

Proprietary cell-penetrating peptide (CPP) technology enables transdermal and alternative delivery of proven GLP-1/GIP therapies—addressing major adherence, access, and convenience barriers.

De-Risked Development Strategy

Focuses on FDA-approved GLP-1 compounds with novel delivery mechanisms, potentially reducing regulatory risk, development timelines, and capital intensity versus new molecular entities.

World-Class Scientific & Global Health Leadership

Leadership and advisors with 700+ peer-reviewed publications, deep clinical trial expertise, and global health commercialization experience across both developed and emerging markets.

Become an Investor

Management Team

Meet the experts behind LIR's novel approaches

Ed Mills, PhD

CEO & Director

Ed Mills, PhD

CEO & Director

Ed Mills, PhD

CEO & Director

Harry Nijjar

CFO and Corporate Secretary

Harry Nijjar

CFO and Corporate Secretary

Harry Nijjar

CFO and Corporate Secretary

Mark Dybul, MD

Strategy Lead and Director

Mark Dybul, MD

Strategy Lead and Director

Mark Dybul, MD

Strategy Lead and Director

Patrick Smith, PhD

Drug Development Lead

Patrick Smith, PhD

Drug Development Lead

Patrick Smith, PhD

Drug Development Lead

Nima Sakian, MD

Medical Lead

Nima Sakian, MD

Medical Lead

Nima Sakian, MD

Medical Lead

Glenn Sammis, PhD

Chemistry Lead

Glenn Sammis, PhD

Chemistry Lead

Glenn Sammis, PhD

Chemistry Lead

Peter Singer, MD

Head of Global Development

Peter Singer, MD

Head of Global Development

Peter Singer, MD

Head of Global Development

How To Invest

LIR Life Sciences trades on the Canadian Securities Exchange (CSE: SKNY) and the Frankfurt Stock Exchange (FSE: N790, WKN: A41QA9). To invest, click below to be redirected to brokerage platforms or search for SKNY on your preferred trading platform.